In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: NeoGenomics is priced slightly above its high-confidence fair value estimate, indicating limited upside potential and some valuation risk. The wide DCF range contrasts sharply with high Price/Sales and EV/Revenue estimates, reflecting mixed growth and profitability expectations. Strong liquidity offsets poor profitability and efficiency, suggesting stable short-term resilience amid valuation uncertainty.